Combination of three cytotoxic agents in small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 413-418

  Stathopoulos, G P ^a   Trafalis, D ^a   Dimitroulis, J ^b   Kosmas, Ch ^c   Stathopoulos, J ^a   Tsavdaridis, D ^d  

^a Errikos Dunant Hospital   (Greece)

^b 6th Pulmonary Clinic   (Greece)

^c Anticancer Hospital   (Greece)

^d Anticancer Hospital   (Greece)

Author keywords

Small cell lung cancer; Three drugs small cell lung cancer; Three drug combination treatment

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PACLITAXEL; SMALL CELL LUNG CARCINOMA;

EID: 84874117419     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2022-8     Document Type: Article

References (27)

1. Loehrer P, Einhorn L, Greco FA (1988) Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 15:2-8
2. Skarlos DV, Samantas E, Kosmidis P et al (1994) Randomised comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5:601-607
3. Jett JR, Everson L, Therneau TM et al (1990) Treatment of limited stage small-cell lung cancer with cyclophosphamide, doxorubicin and vincristine with or without etoposide: a randomised trial of the North Central Cancer Treatment Group. J Clin Oncol 18:33-39
4. Ettinger DS, Finkelstein DM, Ritch PS et al (2002) Study of either ifosfamide or teniposide compared to a standard chemotherapy of extensive disease small-cell lung cancer: an Eastern Cooperative Oncology Group randomised study (E1588). Lung Cancer 37:311-317
5. Lowenbraun S, Birch R, Buchanan R et al (1984) Combination chemotherapy in small cell lung cancer carcinoma: a randomised study of two intensive regimens. Cancer 54:2344-2345
6. Johnson DH, Einhorn LH, Birch R et al (1987) A randomised comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738
7. Fukuoka M, Furuse K, Saijo N et al (1991) Randomised trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861
8. Ettinger DS, Finkelstein DM, Sarma RP et al (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435
9. Loehrer PJ, Rynard S, Ausari R et al (1992) Etoposide ifosfamide and cisplatin in extensive small-cell lung cancer. Cancer 69:669-673
10. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics 2004. CA Cancer J Clin 54:8-15
11. Clark PI, Slevin ML, Joel SP et al (1994) A randomised trial of two etoposide schedules in small-cell lung cancer; the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1435
12. Moore TD, Korn EL (1992) Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst 84:150-158
13. Giaccone G, Ferrari P, Donadio M et al (1987) Reinduction chemotherapy in small-cell lung cancer. Eur J Cancer Clin Oncol 23:1697-1703
14. Sundstrom S, Bremnes RM, Kaasa S et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer. Results from a randomised Phase III trial with five years' follow up. J Clin Oncol 20:4665-4672
15. Roth BJ, Johnson DH, Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291
16. Einhorn LH, Crawford J, Birch R et al (1988) Cisplatin plus etoposide consolidation following cyclopphosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451-456
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
18. Loeher PJ, Ansari R, Gonin R et al (1995) Cisplatin plus etoposide with or without ifosfamide in extensive small cell lung cancer: a Hoosier Oncology Group Study. J Clin Oncol 13:2594-2599
19. Spiro SG, Souhami RL, Geddes DM et al (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59(4):578-583
20. Bleehen NM, Girling DJ, Machin D et al (1993) A randomised trial of three to six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 68(6):1150-1156
21. Giaccone G, Dalesio O, McVie GJ et al (1993) Maintenance chemotherapy in small-cell lung cancer: long term results of a randomised trial. European Organisation for Research and Treatment of Cancer, Lung Cancer Cooperative Group. J Clin Oncol 11(7):1230-1240
22. Sculier JP, Paesmans M, Bureau G et al (1996) Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 14(8):2337-2344
23. Thatcher N, Girling DJ, Hopwood P et al (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity or chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council. Multicenter randomized trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18(2):395-404
24. Pujol JL, Douillard JY, Rivière A et al (1997) Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor 1997 in extensive-stage small-cell lung cancer: a multicenter randomized Phase III study. J Clin Oncol 15(5):2082-2089
25. Mavroudis D, Papadakis E, Veslemes V et al (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small cell lung cancer. Ann Oncol 12:463-470
26. Bunn PA, Kelly K (1997) A Phase I study of cisplatin, etoposide and paclitaxel in small-cell lung cancer. Semin Oncol 24(suppl. 12):144-148
27. Dimitroulis J, Rapti A, Stathopoulos GP et al (2008) Comparison of cisplatin-paclitaxel-etoposide combination versus cisplatin-etoposide in patients with small-cell lung cancer. A Phase III study. Oncol Rep 20:879-884